Side effects of ergotamine

Cephalalgia

Volumn 16, Issue 1, 1996, Pages 5-10

  Meyler, W J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Ergotamine; Literature review; Migraine; Side effects

Indexed keywords

ERGOTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

CONTROLLED STUDY; HEADACHE; HEART INFARCTION; HUMAN; LIMB ISCHEMIA; MIGRAINE; REVIEW; RISK BENEFIT ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOTAMINE; ERGOTISM; EXTREMITIES; HEADACHE; HUMANS; ISCHEMIA; MIGRAINE DISORDERS; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 0030044447     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1996.1601005.x     Document Type: Review

References (34)

1. Thrush D. Does ergotamine work for migraine? In: Warlow C, Garfield J, editors. Dilemmas in the management of the neurological patient. Edinburgh: Churchill Livingstone, 1984:106-13
2. Merhoff GM, Porter JM. Ergot intoxication: historical review and description of unusual clinical manifestations. Ann Surg 1974;180:773-9
3. Barger G. Ergot and ergotism. London: Gurney and Jackson, 1931
4. Gabbai A, Lisbonne P, Pourquier J. Ergot poisoning at Pont St. Espirit. Br Med J 1951;2:650-1
5. Stoll A. Recent investigation of ergot alkaloids. Chem Rev 1950;47:197
6. Maier HW. L'ergotamine inhibitteur du sympathique étudié en clinique, comme moyen d'exploration et comme agent therapeutique. Rev Neurol 1926;33:1104-8
7. Rall TW. Drugs affecting uterine motility. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilmans' the pharmacological basis of therapeutics. New York: Pergamon Press, 1990:933-53
8. Müller-Schweinitzer E. Vascular effects of ergot alkaloids: a study on human basilar arteries. Gen Pharmacol 1983;14:95-102
9. Müller-Schweinitzer E. Ergot alkaloids in migraine: Is the effect via 5HT receptors? In: Olesen J, Saxena PR, editors. 5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press, 1992:297-304
10. Saxena PR, Den Boer MO. Pharmacology of antimigraine drugs. J Neurol 1991;238:S28-35
11. Bax WA, Rezenbrink GJ, Van Heuven-Nolsen D, Thijssen EJ, Bos E, Saxena PR. 5HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharamacol 1993;129:203-10
12. 201Thallium sequential scintigraphy of the myocardium after ergotamine provocation. Dtsch Wochenschr 1980;105:509-15
13. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983;16:695-99
14. Ekbom K, Krabbe AA, Paalzow G, Paalzow L, Tfelt-Hansen P, Waldenlind E. Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study. Cephalagia 1983;3:15-20
15. Tfelt-Hansen P, Ibraheem JJ, Paalzow L. Clinical pharmacology of ergotamine studied with a high performance liquid chromatographic method. In: Rose FC, editor. Advances in migraine research and therapy. New York: Raven Press, 1982:173-9
16. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. Eur J Clin Pharmacol 1982;23:235-40
17. Walker G. ABPI data sheet compendium 1993-94. London: Datapharm Publications, 1994
18. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet 1985;10:334-52
19. Waters WE. Controlled clinical trial of ergotamine tartrate. Br Med J 1970;325-7
20. Yuill GM, Swinburn WR, Liversedge LA. A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine. Br J Clin Pract 1972;26(2):76-9
21. Hakkarainen H, Gustaffson B, Stockman O. A comparative trial of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks. Headache 1978;18:35-9
22. Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1979;2:326-8
23. Dahlof C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-71
24. Hokkanen E, Waltimo O, Kallanranta T. Toxic effects of ergotamine used for migraine. Headache 1978;18:95-8
25. ® and placebo. Clin Ther 1989;11(1):170-82
26. Kinnunen E, Erkinjuntti T, Färkkilä M, Palomäki H, Porras J, Teirmaa H, et al. Placebo-controlled double-blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks. Cephalalgia 1988;8:175-9
27. Pradalier A, Rancurel G, Dordain G, Verdure L, Rascol A, Dry J. Acute migraine attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound Cephalalgia 1985;5:107-13
28. Staffa JA, Lipton R, Stewart WF. The epidemiology of migraine headache. Rev Contemp Pharmacother 1994;5:241-52
29. Diege-Petersen H, Lassen NA, Noer I, Tonnensen KH, Olesen J. Subclinical ergotism. Lancet 1977;2:65-6
30. Ludolph AC, Husstedt IW, Schlake H-P, Grotemeyer K-H, Brune GG. Chronic ergotamine abuse: evidence of functional impairment of long ascending spinal tracts. Eur Neurol 1988;28:311-6
31. Tfelt-Hansen P, Eickhoff JH, Olesen J. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve. Acta Pharmacol Toxicol 1980;47:151-6
32. Tfelt-Hansen P, Olesen J. Arterial response to ergotamine tartrate in abusing and non-abusing migraine patients. Acta Pharmacol Toxicol 1981;48:69-72
33. Panconesi A, Franchi G, Del Bianco PL, Anselmi B, Andreini R, Sicuteri F. Reduced serotonin vascular sensitivity in ergotamine abusers. Cephalalgia 1989;9:259-64
34. Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. New Engl J Med 1966;274:359